ProShares UltraShort Nasdaq Biotechnology (BIS) Annual Income Statement (USD)
BIS Quarterly Financials (USD)
Frequently Asked Questions About ProShares UltraShort Nasdaq Biotechnology (BIS) Stock
ProShares UltraShort Nasdaq Biotechnology's (BIS) last reported annual revenue was USD 110.72 Million.
ProShares UltraShort Nasdaq Biotechnology's (BIS) annual revenue growth rate based on the revenue reported in the past 5 years is : N/A
ProShares UltraShort Nasdaq Biotechnology's(BIS) is profitable as of its last reported annual financials.
The net profit margin for ProShares UltraShort Nasdaq Biotechnology's(BIS) from its laster reported year is 6.08%
The return on equity (ROE) for ProShares UltraShort Nasdaq Biotechnology's(BIS) from its last reported annual financials is : 19.77%
The return on assets (ROA) for ProShares UltraShort Nasdaq Biotechnology's(BIS) from its last reported annual financials is : 9.98%
The return on invested capital (ROIC) for ProShares UltraShort Nasdaq Biotechnology's(BIS) from its last reported annual financials is : 0.00%
The Debt to Equity ratio for ProShares UltraShort Nasdaq Biotechnology's(BIS) from its last reported annual financials is : 0.00%
The dividend yield for ProShares UltraShort Nasdaq Biotechnology's(BIS) from its laster reported year is 4.07%
ProShares UltraShort Nasdaq Biotechnology's(BIS) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Underpriced on free cash flow basis
The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BIS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
